{"protocolSection": {"identificationModule": {"nctId": "NCT00546052", "orgStudyIdInfo": {"id": "0954A-331"}, "secondaryIdInfos": [{"id": "MK0954A-331"}, {"id": "2007_030"}], "organization": {"fullName": "Organon and Co", "class": "INDUSTRY"}, "briefTitle": "A 52 Week Study to Evaluate the Effects of Losartan With or Without HCTZ on Plasma Glucose, Metabolic Parameters, Blood Pressure in Hypertensive Patients With Metabolic Syndrome (0954A-331)", "officialTitle": "52 Week Study to Evaluate the Effects of LOSARTAN 50 mg, 100 mg, 100/12.5 mg HCTZ, 100/25 mg HCTZ on Metabolic Parameters, Blood Pressure and Safety in Hypertensive Patients With Metabolic Syndrome"}, "statusModule": {"statusVerifiedDate": "2022-02", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2005-09-01", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2008-01-01", "type": "ACTUAL"}, "completionDateStruct": {"date": "2008-01-01", "type": "ACTUAL"}, "studyFirstSubmitDate": "2007-10-17", "studyFirstSubmitQcDate": "2007-10-17", "studyFirstPostDateStruct": {"date": "2007-10-18", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2009-01-08", "resultsFirstSubmitQcDate": "2009-05-04", "resultsFirstPostDateStruct": {"date": "2009-06-23", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2024-05-08", "lastUpdatePostDateStruct": {"date": "2024-05-16", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Organon and Co", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "To determine if a one year treatment Losartan with or without HCTZ at different dosages have an effect on metabolic parameters in patients with hypertension and the metabolic syndrome."}, "conditionsModule": {"conditions": ["Hypertension", "Metabolic Disorder"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "NON_RANDOMIZED", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 1738, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "1", "type": "EXPERIMENTAL", "description": "Losartan (MK0954) / Losartan + HCTZ (MK0954A)", "interventionNames": ["Drug: losartan potassium (+) hydrochlorothiazide"]}], "interventions": [{"type": "DRUG", "name": "losartan potassium (+) hydrochlorothiazide", "description": "All patients received Losartan 50mg at Visit 2 titrated to Losartan 100mg (if target BP not achieved) titrated to Losartan 100mg + HCTZ 12.5mg (if necessary) up to Losartan 100mg + HCTZ 25mg. Duration of treatment was one year.", "armGroupLabels": ["1"], "otherNames": ["Cozaar/Hyzaar"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change in Hemoglobin A1c Between 52 Weeks and Baseline", "description": "Absolute Change in Hemoglobin A1c between 52 week measurement and baseline value.", "timeFrame": "52 Weeks - Baseline"}, {"measure": "Change in Fasting Blood Glucose Between Baseline and 52 Weeks Assessments", "description": "Absolute Change in Fasting Blood Glucose Measurements between Baseline and 52 week assessments.", "timeFrame": "52 Weeks - Baseline"}], "secondaryOutcomes": [{"measure": "Target Blood Pressure", "description": "Target Blood Pressure defined as Systolic Blood Pressure/Diastolic Blood Pressure \u2264 140/90 mm Hg at 52 weeks", "timeFrame": "52 Weeks"}, {"measure": "Change in Systolic Blood Pressure Between Baseline and 52 Week Assessments", "description": "Absolute change in Systolic Blood Pressure between baseline and 52 week assessments.", "timeFrame": "52 Weeks - Baseline"}, {"measure": "Change in Diastolic Blood Pressure Between Baseline and 52 Week Assessments", "description": "Absolute change in Diastolic Blood Pressure between baseline and 52 week assessments.", "timeFrame": "52 Weeks - Baseline"}], "otherOutcomes": [{"measure": "Change in Waist Circumference Between Baseline and 52 Week Assessments", "description": "Absolute change in Waist Circumference between baseline and 52 week assessments", "timeFrame": "52 Weeks - Baseline"}, {"measure": "Change in Body Mass Index Between Baseline and 52 Week Assessments", "description": "Absolute change in Body Mass Index Baseline and 52 week assessments", "timeFrame": "52 Weeks - Baseline"}, {"measure": "Percent Change in Low Density Lipoprotein-C Between Baseline and 52 Week Assessments", "description": "Percent Change in LDL-C Between Baseline and 52 week assessments: 100% x \\[(LDL-C 52 Weeks - LDL-C Baseline) / (LDL-C Baseline)\\].", "timeFrame": "52 Weeks - Baseline"}, {"measure": "Percent Change in High Density Lipoprotein-C Between Baseline and 52 Week Assessments", "description": "Percent Change in HDL-C Between Baseline and 52 week assessments: 100% x \\[(HDL-C 52 Weeks - HDL-C 52 Baseline) / (HDL-C Baseline)\\].", "timeFrame": "52 Weeks - Baseline"}, {"measure": "Percent Change in Triglycerides Between Baseline and 52 Week Assessments", "description": "Percent Change in Triglycerides Between Baseline and 52 week assessments: 100% x \\[(Triglycerides 52 Weeks - Triglycerides Baseline) / (Triglycerides Baseline)\\].", "timeFrame": "52 Weeks - Baseline"}, {"measure": "Percent Change in Total Cholesterol Between Baseline and 52 Week Assessments", "description": "Percent Change in Total Cholesterol Between Baseline and 52 week assessments: 100% x \\[(Total Cholesterol 52 weeks - Total Cholesterol Baseline) / (Total Cholesterol Baseline)\\].", "timeFrame": "52 Weeks - Baseline"}, {"measure": "Absolute Change in Uric Acid Between Baseline and 52 Week Assessments", "description": "Absolute Change in Uric Acid Between Baseline and 52 week assessments: Uric Acid 52 weeks - Uric Acid Baseline.", "timeFrame": "52 Weeks - Baseline"}, {"measure": "Absolute Change in C Reactive Protein Between Baseline and 52 Week Assessments", "description": "Absolute Change in C Reactive Protein Between Baseline and 52 week assessments: C Reactive Protein 52 weeks - C Reactive Protein Baseline.", "timeFrame": "52 Weeks - Baseline"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* An Adult Patient (At Least 18 Years Of Age) With A Clinical Identification Of The Metabolic Syndrome Using The IDF Definition:\n\n  * abdominal (central) obesity as defined by the waist circumference in men of \\> 102 cm and women of \\> 88 cm or a BMI equal or greater than 30 kg/m2\n\nand untreated hypertension with bp equal or greater than 140/90 mm Hg but bp \\< 180/110 mm Hg\n\nor a patient receiving one or two antihypertensive agent(s) (diuretics, ace inhibitors, angiotensin ii receptor blockers, calcium channel blockers and beta-blockers will need to be discontinued) and whose blood pressure is not controlled:\n\n* bp equal or greater than 140/90 mm Hg but equal or less than 160/100 mm Hg\n\nor a patient whose hypertension is controlled (\\< 140/90 mm hg) with a single anti-hypertensive agent (diuretics, ace inhibitors, and angiotensin II receptor blockers, calcium channel blockers and beta-blockers will need to be discontinued) but who is unsatisfied or experiencing side effects warranting a discontinuation of the previous treatment and at one of the following:\n\n* Fasting plasma glucose equal or greater than 5.6 mmol/L and \\< 7.0 mmol/L\n* Triglycerides \\> 1.7 mmol/L or specific treatment for this lipid abnormality\n* HDL-c in men \\< 0.9 mmol/L and in women \\< 1.1 mmol/L or specific treatment for this lipid abnormality\n\nExclusion Criteria:\n\n* A Patient With A Diagnosis Of Type II Diabetes Defined As Fasting Blood Glucose Level Equal Or Greater Than 7.0 Mmol/L Or A 2hpg In A 75-G OGTT Equal Or Greater Than 11.1 Mol/L Or Using Any Anti-Hyperglycemic Agents\n* Known Secondary Hypertension Of Any Aetiology (E.G., Uncorrected Renal Artery Stenosis, Malignant Hypertension, Or Hypertensive Encephalopathy)\n* Patient Intolerant To Any Component Of Losartan 50 Mg / Losartan 100 Mg / Losartan 100 Mg + Hctz 12.5 Mg / Losartan 100 Mg + Hctz 25 Mg Or With A Documented History Of Angioedema\n* Patient With Confirmed Clinically Significant Renal Or Hepatic Dysfunction And/Or Electrolyte Imbalance On The Basis Of The Case History Or A Recent Laboratory Test (Serum Creatinine \\> 130 Mmol/L Or Creatinine Clearance \\< 45 Ml/Min, Ast \\> 2 Times Above The Normal Range, Alt \\> 2 Times Above The Normal Range, Serum Potassium \\< 3.5 Or \\> 5.5 Meq/L)\n* Patient With Symptomatic Heart Failure (Classes 3 And 4)\n* Patient With A Prior Myocardial Infarction Or Stroke Within The Last 6 Months\n* Patient Who Has Undergone Percutaneous Coronary Angioplasty Or Coronary Artery Bypass Within The Last 3 Months\n* Pregnant Woman Or A Woman Of Childbearing Potential", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Medical Monitor", "affiliation": "Merck Sharp & Dohme LLC", "role": "STUDY_DIRECTOR"}]}, "referencesModule": {"references": [{"pmid": "20147971", "type": "RESULT", "citation": "Racine N, Hamet P, Sampalis JS, Longo N, Bastien N. A 52-week prospective, cohort study of the effects of losartan with or without hydrochlorothiazide (HCTZ) in hypertensive patients with metabolic syndrome. J Hum Hypertens. 2010 Nov;24(11):739-48. doi: 10.1038/jhh.2010.3. Epub 2010 Feb 11."}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "24 patients not included in the Intention to Treat (ITT) analysis because they did not receive study medication and had no follow up visits. Total ITT population = 1714.", "recruitmentDetails": "First Patient In: 12-Sep-2005 Last Patient In: 29-Dec-2006 Last Patient Last Visit: 31-Jan-08 Total number of Sites (General Practitioners and Family Physicians in Canada): 209", "groups": [{"id": "FG000", "title": "Losartan +/- Hydrochlorothiazide", "description": "Patients could be titrated up from Cozaar 50 mg to Cozaar 100mg to losartan 100 mg + Hydrochlorothiazide 12.5 mg and losartan 100mg/ Hydrochlorothiazide 25 mg, in sequence at any subsequent visits only if needed to obtain Blood Pressure under 140/90 mm Hg."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "1738"}]}, {"type": "Week 4", "achievements": [{"groupId": "FG000", "numSubjects": "1714"}]}, {"type": "Week 8", "achievements": [{"groupId": "FG000", "numSubjects": "1680"}]}, {"type": "Week 12", "achievements": [{"groupId": "FG000", "numSubjects": "1650"}]}, {"type": "Week 32", "achievements": [{"groupId": "FG000", "numSubjects": "1583"}]}, {"type": "Week 52", "achievements": [{"groupId": "FG000", "numSubjects": "1511"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1511"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "227"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "47"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "144"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "9"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "20"}]}, {"type": "Non Compliance", "reasons": [{"groupId": "FG000", "numSubjects": "7"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Losartan +/- Hydrochlorothiazide", "description": "Patients could be titrated up from Cozaar 50 mg to Cozaar 100mg to losartan 100 mg + Hydrochlorothiazide 12.5 mg and losartan 100mg/ Hydrochlorothiazide 25 mg, in sequence at any subsequent visits only if needed to obtain Blood Pressure under 140/90 mm Hg."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "1714"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "54.93", "spread": "11.29"}]}]}]}, {"title": "Age, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "<=45.00", "categories": [{"measurements": [{"groupId": "BG000", "value": "326"}]}]}, {"title": "45.01 - 52.00", "categories": [{"measurements": [{"groupId": "BG000", "value": "359"}]}]}, {"title": "52.01 - 58.00", "categories": [{"measurements": [{"groupId": "BG000", "value": "356"}]}]}, {"title": "58.01 - 65.00", "categories": [{"measurements": [{"groupId": "BG000", "value": "346"}]}]}, {"title": ">=65.00", "categories": [{"measurements": [{"groupId": "BG000", "value": "326"}]}]}, {"title": "Missing", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "734"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "980"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Caucasian", "categories": [{"measurements": [{"groupId": "BG000", "value": "1451"}]}]}, {"title": "Black", "categories": [{"measurements": [{"groupId": "BG000", "value": "32"}]}]}, {"title": "Asian", "categories": [{"measurements": [{"groupId": "BG000", "value": "200"}]}]}, {"title": "Native American", "categories": [{"measurements": [{"groupId": "BG000", "value": "11"}]}]}, {"title": "Other", "categories": [{"measurements": [{"groupId": "BG000", "value": "19"}]}]}, {"title": "Missing", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}]}]}]}, {"title": "Body Mass Index", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Kg/m2", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "33.23", "spread": "5.59"}]}]}]}, {"title": "C-Reactive Protein", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mg/L", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "5.4", "spread": "8.8"}]}]}]}, {"title": "Diastolic Blood Pressure", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mm Hg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "90.54", "spread": "8.16"}]}]}]}, {"title": "Fasting Blood Glucose", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mmol/L", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "5.7", "spread": "0.7"}]}]}]}, {"title": "Heart Rate", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Beats per Minute (BPM)", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "75", "spread": "8.0"}]}]}]}, {"title": "Hemoglobin A1c", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Percent", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "5.71", "spread": "0.59"}]}]}]}, {"title": "High Density Lipoprotein-C", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mol/L", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "1.23", "spread": "0.33"}]}]}]}, {"title": "Low Density Lipoprotein-C", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mmol/L", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "3.17", "spread": "0.93"}]}]}]}, {"title": "Systolic Blood Pressure", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mm Hg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "148.22", "spread": "10.72"}]}]}]}, {"title": "Total Cholesterol", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mmol/L", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "5.36", "spread": "1.05"}]}]}]}, {"title": "Triglycerides", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mmol/L", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "2.16", "spread": "1.16"}]}]}]}, {"title": "Uric Acid", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mmol/L", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "365.8", "spread": "85.4"}]}]}]}, {"title": "Weight", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Kilograms (Kg)", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "92.5", "spread": "18.1"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change in Hemoglobin A1c Between 52 Weeks and Baseline", "description": "Absolute Change in Hemoglobin A1c between 52 week measurement and baseline value.", "populationDescription": "Per Protocol", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percent", "timeFrame": "52 Weeks - Baseline", "groups": [{"id": "OG000", "title": "Losartan +/- Hydrochlorothiazide", "description": "Patients that completed 52 weeks of treatment and were \\>= 80% compliant with the study medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1511"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.04", "spread": "0.62"}]}]}], "analyses": [{"groupIds": ["OG000"], "groupDescription": "Single Cohort Study. Statistical Analysis is based on change from baseline. Null hypothesis value is + 0.5%.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.999", "statisticalMethod": "t-test, 1 sided", "paramType": "Mean Difference (Final Values)", "paramValue": "0.02", "ciPctValue": "95", "ciLowerLimit": "-0.02", "ciUpperLimit": "0.06", "dispersionType": "STANDARD_DEVIATION", "dispersionValue": "0.74"}]}, {"type": "PRIMARY", "title": "Change in Fasting Blood Glucose Between Baseline and 52 Weeks Assessments", "description": "Absolute Change in Fasting Blood Glucose Measurements between Baseline and 52 week assessments.", "populationDescription": "Per Protocol", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmol/L", "timeFrame": "52 Weeks - Baseline", "groups": [{"id": "OG000", "title": "Losartan +/- Hydrochlorothiazide", "description": "Patients that completed 52 weeks of treatment and were \\>= 80% compliant with the study medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1511"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.02", "spread": "0.74"}]}]}], "analyses": [{"groupIds": ["OG000"], "groupDescription": "Single Cohort Study. Statistical Analysis is based on change from baseline. Null hypothesis value is + 0.5mmol/L.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.999", "statisticalMethod": "t-test, 1 sided", "paramType": "Mean Difference (Final Values)", "paramValue": "0.04", "ciPctValue": "95", "ciLowerLimit": "0.01", "ciUpperLimit": "0.07", "dispersionType": "STANDARD_DEVIATION", "dispersionValue": "0.62"}]}, {"type": "SECONDARY", "title": "Target Blood Pressure", "description": "Target Blood Pressure defined as Systolic Blood Pressure/Diastolic Blood Pressure \u2264 140/90 mm Hg at 52 weeks", "populationDescription": "ITT and Per Protocol", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "52 Weeks", "groups": [{"id": "OG000", "title": "Overall Total", "description": "All patients enrolled (signed the informed consent)."}, {"id": "OG001", "title": "Overall Intend to Treat", "description": "All patients enrolled and receiving at least one dose of study drug and having at least one follow up visit."}, {"id": "OG002", "title": "Overall Per Protocol", "description": "All patients completing the 52 week study follow up."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1738"}, {"groupId": "OG001", "value": "1714"}, {"groupId": "OG002", "value": "1511"}]}], "classes": [{"title": "Achieved Target Blood Pressure", "categories": [{"measurements": [{"groupId": "OG000", "value": "1200"}, {"groupId": "OG001", "value": "1200"}, {"groupId": "OG002", "value": "1200"}]}]}, {"title": "Did NOT achieve target Blood Pressure", "categories": [{"measurements": [{"groupId": "OG000", "value": "538"}, {"groupId": "OG001", "value": "514"}, {"groupId": "OG002", "value": "311"}]}]}]}, {"type": "SECONDARY", "title": "Change in Systolic Blood Pressure Between Baseline and 52 Week Assessments", "description": "Absolute change in Systolic Blood Pressure between baseline and 52 week assessments.", "populationDescription": "Per Protocol", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mm Hg", "timeFrame": "52 Weeks - Baseline", "groups": [{"id": "OG000", "title": "Losartan +/- Hydrochlorothiazide", "description": "Patients that completed 52 weeks of treatment and were \\>= 80% compliant with the study medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1511"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-16.95", "spread": "13.34"}]}]}], "analyses": [{"groupIds": ["OG000"], "groupDescription": "Single Cohort Study. Statistical Analysis is based on change from baseline. Null hypothesis value is 0 mm Hg", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.001", "statisticalMethod": "t-test, 2 sided", "paramType": "Mean Difference (Final Values)", "paramValue": "-16.95", "ciPctValue": "95", "ciLowerLimit": "-17.62", "ciUpperLimit": "-16.27", "dispersionType": "STANDARD_DEVIATION", "dispersionValue": "13.34"}]}, {"type": "SECONDARY", "title": "Change in Diastolic Blood Pressure Between Baseline and 52 Week Assessments", "description": "Absolute change in Diastolic Blood Pressure between baseline and 52 week assessments.", "populationDescription": "Per Protocol", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mm Hg", "timeFrame": "52 Weeks - Baseline", "groups": [{"id": "OG000", "title": "Losartan +/- Hydrochlorothiazide", "description": "Patients that completed 52 weeks of treatment and were \\>= 80% compliant with the study medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1511"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-9.84", "spread": "8.93"}]}]}], "analyses": [{"groupIds": ["OG000"], "groupDescription": "Single Cohort Study. Statistical Analysis is based on change from baseline. Null hypothesis value is 0 mm Hg.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.001", "statisticalMethod": "t-test, 2 sided", "paramType": "Mean Difference (Final Values)", "paramValue": "-9.84", "ciPctValue": "95", "ciLowerLimit": "-10.29", "ciUpperLimit": "-9.39", "dispersionType": "STANDARD_DEVIATION", "dispersionValue": "8.39"}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Change in Waist Circumference Between Baseline and 52 Week Assessments", "description": "Absolute change in Waist Circumference between baseline and 52 week assessments", "populationDescription": "Per Protocol", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "cm", "timeFrame": "52 Weeks - Baseline", "groups": [{"id": "OG000", "title": "Losartan +/- Hydrochlorothiazide", "description": "Patients that completed 52 weeks of treatment and were \\>= 80% compliant with the study medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1511"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.28", "spread": "5.44"}]}]}], "analyses": [{"groupIds": ["OG000"], "groupDescription": "Single Cohort Study. Statistical Analysis is based on change from baseline. Null Hypothesis value is 0.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.001", "statisticalMethod": "t-test, 2 sided", "paramType": "Mean Difference (Final Values)", "paramValue": "-1.3", "dispersionType": "STANDARD_DEVIATION", "dispersionValue": "5.4"}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Change in Body Mass Index Between Baseline and 52 Week Assessments", "description": "Absolute change in Body Mass Index Baseline and 52 week assessments", "populationDescription": "Per Protocol", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Kg/m2", "timeFrame": "52 Weeks - Baseline", "groups": [{"id": "OG000", "title": "Losartan +/- Hydrochlorothiazide", "description": "Patients that completed 52 weeks of treatment and were \\>= 80% compliant with the study medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1511"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-7.3", "spread": "5.20"}]}]}], "analyses": [{"groupIds": ["OG000"], "groupDescription": "Single Cohort Study. Statistical Analysis is based on change from baseline. Null Hypothesis value is 0.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.001", "statisticalMethod": "t-test, 2 sided", "paramType": "Mean Difference (Final Values)", "paramValue": "-7.3", "dispersionType": "STANDARD_DEVIATION", "dispersionValue": "5.20"}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Percent Change in Low Density Lipoprotein-C Between Baseline and 52 Week Assessments", "description": "Percent Change in LDL-C Between Baseline and 52 week assessments: 100% x \\[(LDL-C 52 Weeks - LDL-C Baseline) / (LDL-C Baseline)\\].", "populationDescription": "Per Protocol", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percent Change", "timeFrame": "52 Weeks - Baseline", "groups": [{"id": "OG000", "title": "Losartan +/- Hydrochlorothiazide", "description": "Patients that completed 52 weeks of treatment and were \\>= 80% compliant with the study medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1511"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.49", "spread": "32.10"}]}]}], "analyses": [{"groupIds": ["OG000"], "groupDescription": "Single Cohort Study. Statistical Analysis is based on change from baseline. Null Hypothesis value is 0.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.084", "statisticalMethod": "t-test, 2 sided", "paramType": "Mean Difference (Net)", "paramValue": "-1.5", "dispersionType": "STANDARD_DEVIATION", "dispersionValue": "32.1"}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Percent Change in High Density Lipoprotein-C Between Baseline and 52 Week Assessments", "description": "Percent Change in HDL-C Between Baseline and 52 week assessments: 100% x \\[(HDL-C 52 Weeks - HDL-C 52 Baseline) / (HDL-C Baseline)\\].", "populationDescription": "Per Protocol", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percent Change", "timeFrame": "52 Weeks - Baseline", "groups": [{"id": "OG000", "title": "Losartan +/- Hydrochlorothiazide", "description": "Patients that completed 52 weeks of treatment and were \\>= 80% compliant with the study medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1511"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.21", "spread": "17.96"}]}]}], "analyses": [{"groupIds": ["OG000"], "groupDescription": "Single Cohort Study. Statistical Analysis is based on change from baseline. Null Hypothesis value is 0.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.654", "statisticalMethod": "t-test, 2 sided", "paramType": "Mean Difference (Final Values)", "paramValue": "0.2", "dispersionType": "STANDARD_DEVIATION", "dispersionValue": "18.0"}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Percent Change in Triglycerides Between Baseline and 52 Week Assessments", "description": "Percent Change in Triglycerides Between Baseline and 52 week assessments: 100% x \\[(Triglycerides 52 Weeks - Triglycerides Baseline) / (Triglycerides Baseline)\\].", "populationDescription": "Per Protocol", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percent Change", "timeFrame": "52 Weeks - Baseline", "groups": [{"id": "OG000", "title": "Losartan +/- Hydrochlorothiazide", "description": "Patients that completed 52 weeks of treatment and were \\>= 80% compliant with the study medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1511"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.09", "spread": "43.54"}]}]}], "analyses": [{"groupIds": ["OG000"], "groupDescription": "Single Cohort Study. Statistical Analysis is based on change from baseline. Null Hypothesis value is 0.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.336", "statisticalMethod": "t-test, 2 sided", "paramType": "Mean Difference (Final Values)", "paramValue": "-1.1", "dispersionType": "STANDARD_DEVIATION", "dispersionValue": "43.5"}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Percent Change in Total Cholesterol Between Baseline and 52 Week Assessments", "description": "Percent Change in Total Cholesterol Between Baseline and 52 week assessments: 100% x \\[(Total Cholesterol 52 weeks - Total Cholesterol Baseline) / (Total Cholesterol Baseline)\\].", "populationDescription": "Per Protocol", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percent Change", "timeFrame": "52 Weeks - Baseline", "groups": [{"id": "OG000", "title": "Losartan +/- Hydrochlorothiazide", "description": "Patients that completed 52 weeks of treatment and were \\>= 80% compliant with the study medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1511"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-2.98", "spread": "16.97"}]}]}], "analyses": [{"groupIds": ["OG000"], "groupDescription": "Single Cohort Study. Statistical Analysis is based on change from baseline. Null Hypothesis value is 0.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.001", "statisticalMethod": "t-test, 2 sided", "paramType": "Mean Difference (Final Values)", "paramValue": "-3.0", "dispersionType": "STANDARD_DEVIATION", "dispersionValue": "17.0"}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Absolute Change in Uric Acid Between Baseline and 52 Week Assessments", "description": "Absolute Change in Uric Acid Between Baseline and 52 week assessments: Uric Acid 52 weeks - Uric Acid Baseline.", "populationDescription": "Per Protocol", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmol/L", "timeFrame": "52 Weeks - Baseline", "groups": [{"id": "OG000", "title": "Losartan +/- Hydrochlorothiazide", "description": "Patients that completed 52 weeks of treatment and were \\>= 80% compliant with the study medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1511"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-19.17", "spread": "63.84"}]}]}], "analyses": [{"groupIds": ["OG000"], "groupDescription": "Single Cohort Study. Statistical Analysis is based on change from baseline. Null Hypothesis value is 0.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.001", "statisticalMethod": "t-test, 2 sided", "paramType": "Mean Difference (Final Values)", "paramValue": "-19.2", "dispersionType": "STANDARD_DEVIATION", "dispersionValue": "63.8"}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Absolute Change in C Reactive Protein Between Baseline and 52 Week Assessments", "description": "Absolute Change in C Reactive Protein Between Baseline and 52 week assessments: C Reactive Protein 52 weeks - C Reactive Protein Baseline.", "populationDescription": "Per Protocol", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/L", "timeFrame": "52 Weeks - Baseline", "groups": [{"id": "OG000", "title": "Losartan +/- Hydrochlorothiazide", "description": "Patients that completed 52 weeks of treatment and were \\>= 80% compliant with the study medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1511"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.36", "spread": "8.66"}]}]}], "analyses": [{"groupIds": ["OG000"], "groupDescription": "Single Cohort Study. Statistical Analysis is based on change from baseline. Null Hypothesis value is 0.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.613", "statisticalMethod": "t-test, 2 sided", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.4", "dispersionType": "STANDARD_DEVIATION", "dispersionValue": "8.7"}]}]}, "adverseEventsModule": {"frequencyThreshold": "1", "eventGroups": [{"id": "EG000", "title": "Overall ITT", "seriousNumAffected": 35, "seriousNumAtRisk": 1714, "otherNumAffected": 198, "otherNumAtRisk": 1714}], "seriousEvents": [{"term": "Acute coronary syndrome", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1714}]}, {"term": "Acute depression", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1714}]}, {"term": "Acute renal insufficiency", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1714}]}, {"term": "Anaphylactic shock", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1714}]}, {"term": "Anaphylaxis", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1714}]}, {"term": "Ankle fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1714}]}, {"term": "Atherosclerotic cardiovascular disease", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1714}]}, {"term": "Atrial flutter", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 10.", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1714}]}, {"term": "Bronchitis asthmatic", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1714}]}, {"term": "Cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 1714}]}, {"term": "Cardiac catheterization", "organSystem": "Surgical and medical procedures", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1714}]}, {"term": "Cardiomyopathy", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1714}]}, {"term": "Cerebral vascular accident", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 1714}]}, {"term": "Chest Pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1714}]}, {"term": "Death", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 1714}]}, {"term": "Gastric Ulcer", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1714}]}, {"term": "Hip Replacement", "organSystem": "Surgical and medical procedures", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 1714}]}, {"term": "Ileostomy", "organSystem": "Surgical and medical procedures", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1714}]}, {"term": "Infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1714}]}, {"term": "Lymphoma grade IV", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1714}]}, {"term": "Multiple sclerosis aggravated", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1714}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1714}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1714}]}, {"term": "Numbness of Upper Arm", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1714}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1714}]}, {"term": "Rotator Cuff Repair", "organSystem": "Surgical and medical procedures", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1714}]}, {"term": "Single Vessel Disease", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1714}]}, {"term": "Subarachnoid Hemorrhage", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1714}]}, {"term": "Superficial Femoral Arterial Stenosis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1714}]}, {"term": "Ulcer Bleeding Gastric", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1714}]}], "otherEvents": [{"term": "Type 2 diabetes mellitus", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 54, "numAtRisk": 1714}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 35, "numAtRisk": 1714}]}, {"term": "Bronchitis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 29, "numAtRisk": 1714}]}, {"term": "Osteoarthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 23, "numAtRisk": 1714}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 21, "numAtRisk": 1714}]}, {"term": "Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 19, "numAtRisk": 1714}]}, {"term": "Blood Glucose Increased (per investigator's clinical judgment)", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 17, "numAtRisk": 1714}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial."}, "pointOfContact": {"title": "Senior Vice President, Global Clinical Development", "organization": "Merck Sharp & Dohme Corp.", "email": "ClinicalTrialsDisclosure@merck.com", "phone": "1-800-672-6372"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000024821", "term": "Metabolic Syndrome"}, {"id": "D000008659", "term": "Metabolic Diseases"}], "ancestors": [{"id": "D000007333", "term": "Insulin Resistance"}, {"id": "D000006946", "term": "Hyperinsulinism"}, {"id": "D000044882", "term": "Glucose Metabolism Disorders"}], "browseLeaves": [{"id": "M11639", "name": "Metabolic Diseases", "asFound": "Metabolic Disorders", "relevance": "HIGH"}, {"id": "M10024", "name": "Hypertension", "relevance": "LOW"}, {"id": "M16355", "name": "Syndrome", "relevance": "LOW"}, {"id": "M23005", "name": "Metabolic Syndrome", "asFound": "Metabolic Syndrome", "relevance": "HIGH"}, {"id": "M10370", "name": "Insulin Resistance", "relevance": "LOW"}, {"id": "M9997", "name": "Hyperinsulinism", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000019808", "term": "Losartan"}, {"id": "D000006852", "term": "Hydrochlorothiazide"}], "ancestors": [{"id": "D000000889", "term": "Anti-Arrhythmia Agents"}, {"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000047228", "term": "Angiotensin II Type 1 Receptor Blockers"}, {"id": "D000057911", "term": "Angiotensin Receptor Antagonists"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000004232", "term": "Diuretics"}, {"id": "D000045283", "term": "Natriuretic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000049993", "term": "Sodium Chloride Symporter Inhibitors"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}], "browseLeaves": [{"id": "M21701", "name": "Losartan", "asFound": "Gradual", "relevance": "HIGH"}, {"id": "M9910", "name": "Hydrochlorothiazide", "asFound": "Prescription", "relevance": "HIGH"}, {"id": "M4213", "name": "Anti-Arrhythmia Agents", "relevance": "LOW"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M4132", "name": "Angiotensin II", "relevance": "LOW"}, {"id": "M289354", "name": "Giapreza", "relevance": "LOW"}, {"id": "M4135", "name": "Angiotensinogen", "relevance": "LOW"}, {"id": "M25789", "name": "Angiotensin II Type 1 Receptor Blockers", "relevance": "LOW"}, {"id": "M28916", "name": "Angiotensin Receptor Antagonists", "relevance": "LOW"}, {"id": "M7411", "name": "Diuretics", "relevance": "LOW"}, {"id": "M26152", "name": "Sodium Chloride Symporter Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnArAg", "name": "Anti-Arrhythmia Agents"}, {"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "NaAg", "name": "Natriuretic Agents"}, {"abbrev": "VaCoAg", "name": "Vasoconstrictor Agents"}]}}, "hasResults": true}